Eloralintide and Tirzepatide Rat Study

Grogu

GLP-1 Enthusiast
Member Since
Dec 1, 2025
Posts
898
Likes Received
3,369
Location
Coruscant
United-States
Saw this over on TG. At the American Diabetes Association conference this week EL presented data from a rat study on elora administered with tirz.

I think big take away is that the effects of combining the two medications was truly additive. Not too surprising, since that is similar to cagrisema. An interesting thing in the study design is the adjunctive administration of elora. Rats were given two weeks of tirzepatide, followed by adjunctive use of eloralintide at various doses. This mimics what EL must think that will happen in clincial settings (i.e. patient plateaus on tirzepatide and then eloralintide is added). The good news is that addititive weightloss is noted in this arm of the study.

 
Last edited:
I asked AI what would happen if eloralintide was added to retatrutide-

No direct clinical or preclinical data exists yet for combining eloralintide (LY3841136, Lilly’s selective amylin receptor agonist) with retatrutide (LY3437943, Lilly’s GIP/GLP-1/glucagon triple agonist). However, we can make a reasoned prediction based on mechanisms, existing data with similar combinations, and Lilly’s development strategy.

lilly.gcs-web.com

Expected Effects (Hypothetical/Extrapolated)Additive or greater weight loss: Retatrutide already delivers strong results (up to ~24% in Phase 2 and ~28% average in Phase 3 at high doses over ~80 weeks). Eloralintide monotherapy achieved up to ~20% weight loss at 48 weeks. Adding an amylin agonist (which enhances satiety and slows gastric emptying via a distinct pathway) to a potent triple incretin/glucagon agonist should produce complementary effects, similar to how eloralintide added to tirzepatide (dual GIP/GLP-1) showed additive benefits in rat studies. This could push total weight loss higher (potentially 25–30%+ or more in some patients), help overcome plateaus, or improve body composition (more fat loss, relatively less lean mass loss).

delta.larvol.com

Enhanced satiety and appetite control: Amylin agonism targets additional hunger/satiety circuits, which could further suppress food intake beyond what retatrutide achieves through GLP-1/GIP/glucagon pathways.
Metabolic benefits: Potential improvements in glycemic control, energy expenditure (from glucagon in retatrutide), and overall cardiometabolic markers. Amylin agonists may also support better "quality" of weight loss.
Tolerability: Eloralintide was designed for better GI tolerability than earlier non-selective amylin analogs (e.g., less nausea via selectivity for the amylin 1 receptor). However, adding it could still increase GI side effects (nausea, vomiting, constipation) in an additive way, especially during dose escalation. Lilly’s preclinical data with tirzepatide suggests manageable profiles with proper titration.

dom-pubs.onlinelibrary.wiley.com

Lilly’s Approach and Related ResearchLilly explicitly positions eloralintide as a complementary therapy to incretin-based drugs (like tirzepatide or potentially retatrutide). They have:Completed Phase 1 safety/PK studies of eloralintide + tirzepatide.
Ongoing Phase 2 combination studies with tirzepatide.
Phase 3 trials like ENLIGHTEN-6, which evaluates eloralintide added to stable weekly incretin therapy in people with persistent obesity/overweight (this likely includes or is compatible with drugs like retatrutide once approved/available).

trials.lilly.com

Caveats This is investigational — neither drug is approved for combination use, and real-world human results could differ (e.g., due to overlapping side effects, receptor interactions, or individual variability).
Risks could include amplified GI issues, effects on muscle preservation, or other unknowns.
Dosing, titration, and long-term safety would need careful study.

In summary, adding eloralintide to retatrutide would likely result in enhanced, additive weight loss and satiety through complementary mechanisms, with Lilly’s broader program supporting this as a future strategy for patients needing more efficacy or plateau management. Full data would come from future trials.
 
Interesting early data. Basically, tirzepatide + eloralintide caused more weight loss together than either alone in obese rats. Looks like longer appetite suppression was a big factor.

Big catch: this is rat data, not humans yet. But it does seem to show where obesity meds are continuing to head; stacking multiple pathways instead of relying on one drug alone.
 
Interesting early data. Basically, tirzepatide + eloralintide caused more weight loss together than either alone in obese rats. Looks like longer appetite suppression was a big factor.

Big catch: this is rat data, not humans yet. But it does seem to show where obesity meds are continuing to head; stacking multiple pathways instead of relying on one drug alone.

Totally agree that this is only a rat study, but since cagrilintide is additive in humans, chances are that eloralintide will similarly apply to humans. Or at least that's my wishful thinking 🤣.

Can you imagine? 28% on tirzepatide + 20% on eloralintide combined. We're talking a potential huge dent in the obesity epidemic as we know it.
 
Totally agree that this is only a rat study, but since cagrilintide is additive in humans, chances are that eloralintide will similarly apply to humans. Or at least that's my wishful thinking 🤣.

Can you imagine? 28% on tirzepatide + 20% on eloralintide combined. We're talking a potential huge dent in the obesity epidemic as we know it.
Yeah, if the human data ends up even remotely close to that, it could be massive. Tirz already changed the landscape. Adding a strong amylin analog on top could push weight loss into territory we’ve never really seen from meds before.

The big question becomes tolerability. Losing 40–50% body weight sounds amazing until people can’t eat, feel sick constantly, or lose too much lean mass. But if they can balance efficacy with side effects, it’s definitely a glimpse at where anti-obesity treatment is heading.

Let’s keep praying for our rat @chewonmysac 😁
 
Interesting early data. Basically, tirzepatide + eloralintide caused more weight loss together than either alone in obese rats. Looks like longer appetite suppression was a big factor.

Big catch: this is rat data, not humans yet. But it does seem to show where obesity meds are continuing to head; stacking multiple pathways instead of relying on one drug alone.
Speak for yourself. I've already identified as a rat since starting tirzepatide. 🐀

Now I'm just waiting for eloralintide to complete my evolution.
 
Yeah, if the human data ends up even remotely close to that, it could be massive. Tirz already changed the landscape. Adding a strong amylin analog on top could push weight loss into territory we’ve never really seen from meds before.

And results not even seen with gastric surgery. This combo could be the death kneel for surgical interventions in most cases.

The big question becomes tolerability. Losing 40–50% body weight sounds amazing until people can’t eat, feel sick constantly, or lose too much lean mass. But if they can balance efficacy with side effects, it’s definitely a glimpse at where anti-obesity treatment is heading.

Let’s keep praying for our rat @chewonmysac 😁

YES, prayers and thoughts with @chewonmysac . He’s paving the way for the rest of us.
 
Saw this over on TG. At the American Diabetes Association conference this week EL presented data from a rat study on elora administered with tirz.

I think big take away is that the effects of combining the two medications was truly additive. Not too surprising, since that is similar to cagrisema. An interesting thing in the study design is the adjunctive administration of elora. Rats were given two weeks of tirzepatide, followed by adjunctive use of eloralintide at various doses. This mimics what EL must think that will happen in clincial settings (i.e. patient plateaus on tirzepatide and then eloralintide is added). The good news is that addititive weightloss is noted in this arm of the study.

Thanks for that link. I am very interested in Elora and Reta, but these rat studies certainly drove home the point of the combined effect. I took a screen shot of the charts showing the additive effect of Elora and Tirz in rats.

1780867542150.webp
 
Thanks for that link. I am very interested in Elora and Reta, but these rat studies certainly drove home the point of the combined effect. I took a screen shot of the charts showing the additive effect of Elora and Tirz in rats.

View attachment 26671

Yeah, I'm super interested in elora too! Just the entire idea that there are "other" pathways to crack the same problem and that it looks like this medication can be stacked on top of what we already have is fantastic.

Thanks for posting the screenshot! The top right hand quadrant is the one that is really exciting to me and specifically the red line.
 
Thanks for that link. I am very interested in Elora and Reta, but these rat studies certainly drove home the point of the combined effect. I took a screen shot of the charts showing the additive effect of Elora and Tirz in rats.

View attachment 26671
There are some interesting trends hiding in the graphs if one takes the time to spot them:

The "co-administration" food intake graph suggests that elora (as administered) seems to have a more stable/predictable effect on appetite than tirz (or tirz + elora). With tirz you see one heavy day of eating followed by two lighter days of eating. Meanwhile elora has much less day to day variability in eating.

The 3 day cadence for tirz is to be expected, since the drug was dosed every 3rd day in this trial and elora being more stable makes sense since due to a longer half-life, there would be less day to day variability in serum concentration of elora VS tirz.

With tirz alone, you had two days of appetite suppression followed by a 3rd day in which the rats would "pig out" and eat more than the control rats on those days. Meanwhile, once saturated, the elora rats appear to have even more stable day to day appetite levels than the control rats.

Meanwhile, the elora rats in the same "co-administration" food graph returned to eating nearly the same amount of food as the control rats at about 3 weeks into the trial, which is certainly an interesting result. Normally (for diet induced weight loss), a reduced average daily intake level would be maintained (to the extent that a given weight loss result is maintained). I mean the average is technically lower, but not that much lower as one closes in on the end of the trial.

This tells me that the "calories" tracking/obsessed folks will likely do better psychologically on elora than on a GLP unless they're taking more frequent GLP doses to smooth out day to day variability or they're employing other means (e.g. diet composition changes to help manage appetite). The trial can't inform on the latter since the rats presumably are being fed some standardized chow of uniform composition.

Moving onto the "adjunctive" graph. It's interesting just how much appetite is crushed (and for two full shot cycles) on the tirz + max elora graph. Even though at this point tirz had already plateaued before the elora was added, it crushes appetite nearly as much as it did for the first two cycles on the co-administration graph (where both tirz and elora were started at the same time). It's not looking like longer-term this impacts the overall weight loss plateau, but it's wild that overall food consumption seems to track so similarly with the red squares on both graphs (despite one representing a rat new to GLPs and one represents an "experienced" GLP rat).
 
Actually wasn't it around 350 bucks a kit from Uther or something like that? Yeah that's a lot especially since it wasn't even a very large kit hopefully we're going to hear a lot more about this going forward.
 
Unless I do not know what kit means - but $25/vial - is that a lot?
l oh I got you, so I was pretty sure wrong about that it was actually 350 a kit, which would make it 35 a vial. But I think that the milligram for the each vial was like 5 mg or something ridiculously small I honestly can't remember but I think 5 mg for 35 a vial is a lot. Imagine paying 35 a vial for 5 mg of tirz.
 
And results not even seen with gastric surgery. This combo could be the death kneel for surgical interventions in most cases.



YES, prayers and thoughts with @chewonmysac . He’s paving the way for the rest of us.
Reta is almost at gastric surgery level by itself. When they roll out a quad agonist I would be surprised if they aren't out performing it. Obviously sides are big but compared to literally having your stomach permanently surgically altered they are much better. I think once we see the triple and quad agonists really take off the next class of drugs will be maintenance drugs.
 
Unless I do not know what kit means - but $25/vial - is that a lot? lol

Exactly what @Gr33dyOctopus said. The cost is actually $350 directly from Uther, but that's not the issue, the "issue" is that eloralintide (at least on it's own) has higher dosing than say cagrilintide. In the eloralintide clinical trials, the 6mg and 9mg arms out performed lower doses. So, a 10mg vial might only last a week or two depending on the dose. The current Uther batch tested at slighted above 13mg, so at 6mg, that's only 2 weeks per vial.
 
I think once we see the triple and quad agonists really take off the next class of drugs will be maintenance drugs.

I'm not sure about that. I think that there is a bigger problem that needs to be addressed first and I think eloralintide is exactly what EL is thinking. And it's the elephant in the room.... that being that folks who have higher body weight reductions targets are less likely to be successful. We see this across this entire class of medications. They need to fix that first. First picture below is elora and second is reta.

Maintenance is easy. Just keep taking the medication.



1780877887810.webp

1780878086264.webp
 
Actually wasn't it around 350 bucks a kit from Uther or something like that? Yeah that's a lot especially since it wasn't even a very large kit hopefully we're going to hear a lot more about this going forward.
WW just opened their buy for $315/kit but it comes with a $33 testing fee adder and a $10 admin fee. There’s another group that will supposedly release their pricing tomorrow and says they’ll beat everyone else on pricing.

I don’t have any interest in the product myself. I just find the discussion and the market interesting.

Like Grogu and others have pointed out, it has the potential to require quite a bit of product. I think the hope amongst those who are interested is that is effective as a smaller supplement to an existing GLP protocol.
 
1780867542150.webp
Thanks for posting the study and the graph.

For those considering eloralintide early while it is still expensive, the top right graph says something about that. Elora at 1nmol/kg did nothing much but at 10nmol/kg caused an additional 5% weight loss , where 10 times that dose caused an additional 10% weight loss. While this is not remotely the same as human evidence, it does suggest that the response is not linear with respect to doses. Assuming the high dose is chosen to cause 10% weight loss on its own, and about the same as the dose of tirz used in the study, then 1/10 of that dose still caused an additional 5% weight loss, which suggests that low dose add on elora might work better than expected if it does something similar in humans. And if it could add another 10% to reta's weight loss at higher doses it would be a huge advance, 40% weight loss would be enough to fix anything but the most severe obesity, and even if worse than that still make a huge difference to health if still a bit overweight at the end.

Feel a bit sorry for the poor rats started on 100nmol/kg of elora with tirz , no food intake for nearly a week in a rat is a pretty long time. I cannot imagine that did not come with some side effects, rats don't vomit so it is harder to tell, but it suggests jumping to a high dose of elora suddenly if already on tirz could be most unpleasant, something like a month of no eating presumably with side effects that fit with that. Which to me sounds like good chance of ending up in hospital on a drip. It does suggest considerable care should be taken with doses in those experimenting with elora early, where starting low and going slow is probably essential.
 
If the doses in the trial using elora and tirz is 1 (assuming this is a starting dose),3,6 and 9mg, a 10mg vial could be for 2-3 weeks for a while.
 
Like Grogu and others have pointed out, it has the potential to require quite a bit of product. I think the hope amongst those who are interested is that is effective as a smaller supplement to an existing GLP protocol.

Yes, I’m hoping that not too much is needed on top of my current tirzepatide dose. From those providing accounts of their experiences thus far, most are starting at 500mcg or 1mg. If those low doses are effective, then we’ll be faced with a different problem…. how long to keep a reconstituted vial of a peptide that’s probably sticky and prone to aggregation.

If the doses in the trial using elora and tirz is 1 (assuming this is a starting dose),3,6 and 9mg, a 10mg vial could be for 2-3 weeks for a while.

As @Dos-Dox mentioned, most people will probably be stacking, but eloralintide on it’s own might be something for those who are resistant or can’t tolerate tirz or reta. On it’s own, if someone needs 9mg, that’s 1 week per vial, with a little left over.
 
release their pricing tomorrow and says they’ll beat everyone else on pricing.
New group pricing has been released at $200/kit (or $110/half) with $20 shipping. So now you all have a choice between Uther with an established GB (for more $$$) or Changsha with a new GB (for less $$).

Competition is good.
 
I'm not sure about that. I think that there is a bigger problem that needs to be addressed first and I think eloralintide is exactly what EL is thinking. And it's the elephant in the room.... that being that folks who have higher body weight reductions targets are less likely to be successful. We see this across this entire class of medications. They need to fix that first. First picture below is elora and second is reta.

Maintenance is easy. Just keep taking the medication.



View attachment 26682

View attachment 26683
Absolutely if you weigh 450 and your target weight should be 180 then losing 150 pounds is just a start and still leaves you 100 pounds overweight. Solving for 270lbs of weight loss with medication seems like it's going to be extent difficult but we said that about 100lbs of weight loss a few years ago so you never know.
 
Absolutely if you weigh 450 and your target weight should be 180 then losing 150 pounds is just a start and still leaves you 100 pounds overweight. Solving for 270lbs of weight loss with medication seems like it's going to be extent difficult but we said that about 100lbs of weight loss a few years ago so you never know.

Yeah, I think it's going to be tough to solve the 450lb person issue. I can tell you first hand, because I was 455lbs in 2003. Had a gastric bypass that year and lost to 245lbs. Amazing outcome, probably saved my life and was a 46% excess weight loss. But still short of the 205, that would put me in "normal" weight ranges by most measures. If I could have started tirzeaptide then, I would have made it to goal. Elora + Tirz or Reta would have probably brought me to the same 46% weight loss or 245lbs as the surgery. Still well short of "normal" weight for my height/frame.

I'm 215 this morning and can see "normal weight" on the horizon.
 
Yeah, I think it's going to be tough to solve the 450lb person issue. I can tell you first hand, because I was 455lbs in 2003. Had a gastric bypass that year and lost to 245lbs. Amazing outcome, probably saved my life and was a 46% excess weight loss. But still short of the 205, that would put me in "normal" weight ranges by most measures. If I could have started tirzeaptide then, I would have made it to goal. Elora + Tirz or Reta would have probably brought me to the same 46% weight loss or 245lbs as the surgery. Still well short of "normal" weight for my height/frame.

I'm 215 this morning and can see "normal weight" on the horizon.
Congrats!

I am looking for solutions for my landlord that is 450, with a high of about 600. He's currently taking a high 20mg dose of reta/tirz and needs something more. Ive been debating Cagri...
 
New group pricing has been released at $200/kit (or $110/half) with $20 shipping. So now you all have a choice between Uther with an established GB (for more $$$) or Changsha with a new GB (for less $$).

Competition is good.
How do you get in the group buy?
 
Congrats!

I am looking for solutions for my landlord that is 450, with a high of about 600. He's currently taking a high 20mg dose of reta/tirz and needs something more. Ive been debating Cagri...

Thanks! It's been a long long fight against obesity for sure.

Cagri is rough with the fatigue and some suffer from GI sides, but it definitely hits the right receptors in me.

I'm going to seriously date myself here, but cagri honestly reminds me of Fen-Phen from the early 1990s. If anyone was on that back in the day, appeptite didn't just diminish, it became alien. Food simply stopped being interesting. I would often look at a meal genuinely indifferent, not just "not hungry". So far, that's what cagri has done for me. I'm still eating, but food is the last thing on my mind. Too much cagri, I could probably stop eating all together.
 

Trending Topics

Latest Posts

Forum Statistics

Threads
17,585
Posts
182,520
Members
59,172
Newest
onicayunq
Back
Top Bottom